MME Calculator — Morphine Milligram Equivalents

About the MME Calculator — Morphine Milligram Equivalents

Morphine milligram equivalents (MME) provide a common scale for comparing opioid exposure across different medications. CDC prescribing guidance uses daily MME bands as caution points for risk review, especially once the total reaches or exceeds 50 MME/day. Higher daily MME is associated with progressively higher overdose risk in observational studies, but the number is still only one part of the full clinical picture.

This calculator converts up to three concurrent opioids to total daily MME using widely cited equianalgesic conversion factors from CDC, CMS, and clinical pharmacology references. It shows the contribution of each medication, adds overdose-risk context, highlights benzodiazepine co-use, and flags ranges where naloxone access is commonly reviewed.

Equianalgesic conversions remain approximations with substantial inter-patient variability. Methadone conversions are especially complex because the ratio changes with dose, the half-life is long and variable, and QTc risk can matter. When clinicians compare opioid rotation scenarios, many references apply a 25-50% reduction for incomplete cross-tolerance rather than treating the raw MME output as a direct new-dose instruction.

When This Page Helps

MME calculation helps compare opioid regimens on a common scale so total daily exposure is easier to review. This calculator combines multiple opioids, shows the contribution of each medication, and highlights dose ranges that deserve closer clinical review.

How to Use the Inputs

1. Select the first opioid medication from the dropdown list.
2. Enter the dose per administration and number of times per day.
3. Optionally add a second and third opioid for combination therapy.
4. Indicate concurrent benzodiazepine use for interaction assessment.
5. Indicate whether naloxone has been prescribed.
6. Review total daily MME, the worksheet risk band, overdose-risk context, and naloxone review context.

Example Calculation

Tips & Best Practices

• When clinicians compare opioid-rotation scenarios, many references reduce the raw equianalgesic total by 25-50% for incomplete cross-tolerance.
• Methadone totals deserve extra caution because the conversion ratio changes with dose and does not behave like a simple linear swap.
• If multiple prescribers are involved, the total works best when reconciled against PDMP or medication-list review rather than against one prescription in isolation.
• Fentanyl patches have delayed onset and offset, so patch-to-short-acting comparisons need more caution than the MME number alone suggests.
• Concurrent benzodiazepines can raise overdose risk even when the MME total itself does not look extreme.
• Use the total to support a broader pain-management review, not to crowd out function, side effects, or non-opioid strategies.

Understanding the CDC Guideline Revision

The current CDC Clinical Practice Guideline replaced the earlier version that was sometimes misapplied as inflexible dose limits leading to patient harm through forced tapers. The revision emphasizes individualized assessment, shared decision-making, and avoidance of abrupt discontinuation. Key recommendations include using the lowest effective dose, avoiding increases to ≥ 50 MME/day without reassessment, considering naloxone access at ≥ 50 MME/day, and using PDMP data to identify concurrent prescriptions. The guideline explicitly states that specific numeric thresholds should not be applied as rigid ceilings — clinical judgment remains paramount.

The Opioid Epidemic Context

Recent U.S. data show tens of thousands of opioid-involved overdose deaths annually. While the broader overdose crisis is driven largely by illicitly manufactured fentanyl, prescription opioid misuse remains a significant contributor, and many people with opioid use disorder first encountered opioids through prescriptions. MME review, PDMP review, naloxone-access discussions, and multimodal pain management are all part of the broader safety context around prescription opioids.

Opioid Rotation Principles

Opioid rotation (switching from one opioid to another) is one setting where MME tables are often used, especially when the regimen being reviewed is not fitting well. A common comparison workflow is to total the daily MME, translate it through equianalgesic ratios, then apply a cross-tolerance reduction rather than treating the raw conversion as a direct new-dose instruction. That is why this page works best as a review worksheet, not as a rotation order set.

Frequently Asked Questions

• What is a morphine milligram equivalent (MME)?

  An MME is a conversion factor that expresses the dose of any opioid as the equivalent dose of oral morphine. For example, 10 mg of oral oxycodone has a conversion factor of 1.5, so it equals 15 MME. This standardization allows comparison of total opioid burden across different medications. The CDC uses MME thresholds to guide prescribing risk assessment.

• Why is the 90 MME/day threshold important?

  Epidemiologic studies show that patients on ≥ 90 MME/day have substantially higher overdose risk than patients on < 20 MME/day. CDC guidance treats ≥50 and ≥90 MME/day as caution points for closer reassessment, not as rigid dose ceilings. Some patients with cancer pain, palliative needs, or unusual opioid histories may still sit above those bands, which is why the total works best as review context rather than as a stand-alone rule.

• Why are methadone conversions so complicated?

  Methadone has unique pharmacology: incomplete cross-tolerance with other mu-opioid agonists, NMDA receptor antagonism, dose-dependent conversion ratios (the ratio increases dramatically at higher doses), extremely long and variable half-life (8-59 hours), and risk of QTc prolongation and torsades de pointes. A patient on morphine 60 mg/day converts to methadone at a 4:1 ratio, but a patient on morphine 300 mg/day converts at 12:1. Methadone rotations should only be performed by experienced clinicians with careful monitoring.

• When does naloxone usually enter the discussion?

  CDC guidance highlights naloxone access for patients on ≥50 MME/day, concurrent benzodiazepines, history of overdose or substance use disorder, or other factors that increase overdose risk. This page therefore uses naloxone as review context, not as a substitute for clinician judgment about whether a specific patient should have naloxone on hand.

• Are these conversion factors exact?

  No. Equianalgesic ratios are based on limited studies and have significant inter-patient variability (often 2-5 fold). Factors affecting individual response include genetics, organ function, age, concurrent medications, and tolerance. When clinicians compare a possible opioid rotation, many references reduce the raw equianalgesic total by 25-50% instead of treating the calculator output as a direct replacement dose.

• Does the CDC guideline apply to cancer pain and palliative care?

  The CDC Clinical Practice Guideline is intended for outpatient clinicians prescribing opioids for chronic pain in adults, excluding pain management related to sickle cell disease, cancer-related pain treatment, palliative care, and end-of-life care. Patients with cancer pain or those receiving palliative or hospice care may appropriately need higher opioid doses without the same threshold-based restrictions.